News | July 06, 2024
Biogen completes acquisition of HI-Bio
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Thermo Fisher has equipped this Centre for Innovation with state-of-the-art platforms such as CellInsight CX7 LZR Pro High Content Screening Platform
Subscribe To Our Newsletter & Stay Updated
